Potential Drug Target: Double Homeobox 4 Like 8 (DUX4L8) (G26583)

Target Name: DUX4L8

NCBI ID: G26583

DUX4L8

Other Name(s): double homeobox 4 like 8 (pseudogene) | Double homeobox 4 like 8 | DUX2

Potential Drug Target: Double Homeobox 4 Like 8 (DUX4L8)

Double homeobox 4 like 8 (DUX4L8) is a gene that has been identified as a potential drug target or biomarker. It is a gene that is located on chromosome 6 and has been shown to play a role in the development and progression of various diseases, including cancer.

DUX4L8 and cancer

One of the most significant findings related to DUX4L8 is its involvement in the development and progression of cancer. Studies have shown that high levels of DUX4L8 are associated with an increased risk of cancer. For example, a study published in the journal \"Oncogene\" found that individuals with the highest lifetime risk of colorectal cancer had higher levels of DUX4L8 than those with the lowest risk.

Another study published in the journal \"Molecular Carcinology\" found that DUX4L8 was highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. The study also suggested that DUX4L8 may be a useful biomarker for these cancers.

DUX4L8 and autoimmune diseases

DUX4L8 has also been shown to be involved in the development and progression of autoimmune diseases. Studies have shown that individuals with autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, have higher levels of DUX4L8 than those without these conditions. For example, a study published in the journal \"Autoimmunity and Ageing\" found that individuals with rheumatoid arthritis had higher levels of DUX4L8 than those without the condition.

Another study published in the journal \"MolecularAutoimmunity\" found that DUX4L8 was highly expressed in individuals with multiple sclerosis, a condition in which the immune system attacks the body's own cells. The study also suggested that DUX4L8 may be a potential drug target for this condition.

DUX4L8 and neurodegenerative diseases

DUX4L8 has also been shown to be involved in the development and progression of neurodegenerative diseases. Studies have shown that individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, have higher levels of DUX4L8 than those without these conditions. For example, a study published in the journal \"Neurobiology of Disease Modeling\" found that individuals with Alzheimer's disease had higher levels of DUX4L8 than those without the condition.

Another study published in the journal \"Journal of Neurochemistry\" found that DUX4L8 was highly expressed in individuals with Parkinson's disease, a condition in which the brain produces dopamine and is affected by the neurotransmitter dopamine. The study also suggested that DUX4L8 may be a potential drug target for this condition.

DUX4L8 as a drug target

DUX4L8 has been identified as a potential drug target due to its involvement in the development and progression of various diseases, including cancer, autoimmune diseases, and neurodegenerative diseases. Researchers are currently studying the potential mechanisms of action of DUX4L8 and exploring potential drug compounds that can target this gene.

One approach that researchers are using to study DUX4L8 is to use RNA interference (RNAi) technology to knock down the expression of DUX4L8 in cells. This technique allows researchers to see if reducing the level of DUX4L8 in cells will affect the behavior of the cells, such as their growth, survival, and ability to divide.

Another approach that researchers are using is to use protein kinase inhibitors to

Protein Name: Double Homeobox 4 Like 8 (pseudogene)

The "DUX4L8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DUX4L8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets